Effects of hyperbaric oxygen therapy on circulating interleukin-8, nitric oxide, and insulin-like growth factors in patients with type 2 diabetes mellitus.
BACKGROUND
The potential benefits of hyperbaric oxygen therapy (HBOT) have been reported in diabetic patients with foot ulcers. However, the roles of HBOT on wound healing-associated growth factors and inflammatory mediators are not completely understood in diabetes mellitus (DM).


OBJECTIVE
The aim of this study was to investigate the effects of HBOT on circulating cytokines, NO, and insulin-like growth factors (IGF) in patients with type 2 DM.


METHODS
Serum samples were collected from patients with type 2 DM (n=31) and healthy subjects (n=29) before (baseline) and after the first and third exposure.


RESULTS
Before HBOT, body mass index (BMI) and serum HbA1c were significantly greater, whereas serum IGF-I was significantly lower in diabetic patients compared to healthy subjects (one-way ANOVA, p<0.05). After adjusting for age, gender, and BMI, serum insulin, growth hormone (GH), IGF-II, IGF-binding protein (IGFBP)-1, IGFBP-3, leptin, interleukin (IL)-8, and NO were not significantly altered by HBOT in diabetic patients and healthy subjects (repeated-measures ANOVA). Change in serum insulin (baseline to the third exposure) was a positive predictor of changes in leptin and NO in healthy subjects and diabetic patients, respectively.


CONCLUSIONS
Our results suggest that short-term HBOT may not alter the circulating insulin, IGF, leptin, IL-8, and NO levels. In addition, healthy subjects and diabetic patients showed differential responses to HBOT in the relationships of leptin, insulin, and NO. Further studies are needed to clarify the mechanism of HBOT-improved wound healing in diabetic patients with foot ulcers.
Chen
Shih-Jen
SJ
Department of Orthopedic Surgery, Changhua Christian Hospital, Changhua 500, Taiwan.
Yu
Chen-Tung
CT
Cheng
Ya-Ling
YL
Yu
Shi-Yau
SY
Lo
Hui-Chen
HC
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging; D015992:Body Mass Index; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000628:therapy*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D006931:Hyperbaric Oxygenation / Q000009:adverse effects*; D007328:Insulin / Q000097:blood; D018969:Insulin-Like Growth Factor Binding Proteins / Q000097:blood; D016209:Interleukin-8 / Q000097:blood*; D020738:Leptin / Q000097:blood; D008297:Male; D008875:Middle Aged; D009569:Nitric Oxide / Q000097:blood*; D012044:Regression Analysis; D013002:Somatomedins / Q000032:analysis*
D006442:Glycated Hemoglobin; D013006:Growth Hormone; D007328:Insulin; D018969:Insulin-Like Growth Factor Binding Proteins; D016209:Interleukin-8; D020738:Leptin; D009569:Nitric Oxide; D013002:Somatomedins